SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 90.36M
March 31, 2026 91.48M
December 31, 2025 89.16M
September 30, 2025 94.34M
June 30, 2025 95.98M
March 31, 2025 98.79M
December 31, 2024 100.83M
September 30, 2024 100.29M
June 30, 2024 103.40M
March 31, 2024 106.78M
December 31, 2023 108.89M
September 30, 2023 113.93M
June 30, 2023 118.97M
Date Value
March 31, 2023 120.34M
December 31, 2022 120.06M
September 30, 2022 114.46M
June 30, 2022 103.71M
March 31, 2022 90.04M
December 31, 2021 76.19M
September 30, 2021 65.28M
June 30, 2021 55.71M
March 31, 2021 45.62M
December 31, 2020 41.74M
September 30, 2020 29.57M
June 30, 2020 18.34M
March 31, 2020 10.68M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Integra LifeSciences Holdings Corp. 688.98M
Abbott Laboratories 13.94B
AngioDynamics, Inc. 116.41M
Alphatec Holdings, Inc. 524.06M
AtriCure, Inc. 323.68M